about
Nano delivers big: designing molecular missiles for cancer therapeutics.Proteomic analysis of bladder cancer indicates Prx-I as a key molecule in BI-TK/GCV treatment system.EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse modelEvaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse modelAdenoviral delivery of the EMX2 gene suppresses growth in human gastric cancer.Emerging strategies for EphA2 receptor targeting for cancer therapeutics.Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosaRegulation of the target protein (transgene) expression in the adenovirus vector using agonists of toll-like receptors.Proliferation inhibition and apoptosis enhancement of human cervical cancer cells by ultrasound-targeted microbubble destruction delivered double suicide genes.Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer.Adenovirus composition, proteolysis, and disassembly studied by in-depth qualitative and quantitative proteomicsPersistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell linesSequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancerIn vitro and in vivo double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for PC-3 cell line.Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection.EMX2 gene expression predicts liver metastasis and survival in colorectal cancer.155R is a novel structural protein of bovine adenovirus type 3, but it is not essential for virus replication.Expression of HIF-1α ODD domain fused canine caspase 3 by EGFR promoter-driven adenovirus vector induces cytotoxicity in canine breast tumor cells under hypoxia.Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).Herpesvirus saimiri-based endothelin-converting enzyme-1 shRNA expression decreases prostate cancer cell invasion and migration.Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell.Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA.The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma.Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer.
P2860
Q30470080-9463978A-2175-4375-B47E-CAC46DF49292Q31164666-EA5E2996-D149-4295-9949-D302158BA3E7Q33924763-28DEA535-E69F-4885-84C1-E279288B7D0BQ34153735-5919A844-3D02-44C2-9F04-B107175A85B5Q34430506-CE3AA3D2-B819-4127-BBE4-2A4ADB7FD140Q34469271-A30C403C-B683-4984-8A3E-138098845270Q34599868-3186A4EF-313D-4DC8-8261-0017252C4C3FQ34750424-D76BEA70-2A16-4790-9121-C9E797341967Q35017160-BFC5D590-6A11-4AEC-81B2-40D20ED2AC58Q35085995-A4C96484-7568-4A85-BDA7-6C4E8D41D988Q35109904-13F02BD0-CAC4-4A78-BA1B-1FD622342041Q35393576-BECF46BE-66F1-4E87-8B19-539F09A4819DQ35672866-DFA474DB-B312-4C3D-AB7D-1C0DC6105B57Q35768818-532FEC1D-9101-4FA9-92A9-349C15D20883Q37742680-EA45BD77-7781-43BC-8E73-EFE107395C87Q38613759-E8ECDEDB-59B8-4F3E-BDC4-E77E37898B80Q38721445-61DF3DCB-A98E-4DCA-8A66-7228442626A5Q38741055-87F2F1AE-DEBC-4651-BC13-CF9905DF8445Q38811077-DAF5DE85-AB59-4581-B947-1EFA04E1BAEAQ38980455-4197E9D8-D4E6-4748-B808-45051A84935CQ39212805-C78DAD58-B40B-404C-B148-D17B4935B877Q39293750-A90D5896-4DD7-4B05-B07D-508F396F0410Q39643724-7DDE114A-4B79-4B74-BCD2-C002300BA285Q39688817-3947ED2D-B971-4693-964B-279994B794C5Q43727484-E5EFACC0-5CD9-4282-86C2-39F6D103B605Q45362340-EE85C2A7-579A-416C-A609-C6DD8006BD6CQ45875794-F79E7F91-165D-449B-8D75-03B1F1E17EB1
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adenoviral vector-based strategies for cancer therapy.
@en
Adenoviral vector-based strategies for cancer therapy.
@nl
type
label
Adenoviral vector-based strategies for cancer therapy.
@en
Adenoviral vector-based strategies for cancer therapy.
@nl
prefLabel
Adenoviral vector-based strategies for cancer therapy.
@en
Adenoviral vector-based strategies for cancer therapy.
@nl
P2093
P2860
P1433
P1476
Adenoviral vector-based strategies for cancer therapy.
@en
P2093
Anurag Sharma
Dinesh S Bangari
Manish Tandon
Suresh K Mittal
P2860
P304
P356
10.2174/157488509788185123
P577
2009-05-01T00:00:00Z